TY - JOUR AU - Yuan, Yonggang AU - Huang, Qingyuan AU - Gu, Chang AU - Chen, Haiquan PY - 2017 TI - Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis JF - Journal of Thoracic Disease; Vol 9, No 12 (December 29, 2017): Journal of Thoracic Disease Y2 - 2017 KW - N2 - Background: A previous meta-analysis of our research team suggested survival advantage from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) after surgery in patients with EGFRmutant non-small cell lung cancer (NSCLC). This study aims to follow up on the findings of the previous one and presents our latest updates through the past few years. Methods: The study advanced the previous meta-analysis and included a comprehensive range of relevant studies in PubMed. Disease-free survival (DFS) with hazard ratios (HRs) was calculated using random and/ or fixed-effects models. Subgroup analysis and meta-regression analysis were also performed. Results: A total of 2,223 patients in seven studies were eligible for the analysis. Adjuvant EGFR-TKIs administration was significantly associated with superior DFS [HR, 0.60; 95% confidence interval (CI), 0.42–0.87], corresponding to an absolute benefit of 3.4% at 3 years, yet with significant heterogeneity (I2=80.0%, P Conclusions: The updated meta-analysis provided strengthened evidence of significant DFS advantage of adjuvant EGFR-TKI treatment for patients with EGFR-mutant NSCLC after complete resection. UR - https://jtd.amegroups.org/article/view/17842